More recently, an alternative method to deliver CRISPR/Cas9 constructs targeting Nf1 and Trp53 via muscle electroporation (EPO) was shown to generate sarcomas that resemble those obtained using conventional modeling techniques12. This evidence concerns the gene EPO and sarcoma.